Candel Therapeutics, Inc.
CADL- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001841387
In the last 90 days, Candel Therapeutics, Inc. insiders filed 0 open-market purchases and 2 sales; 137 institutions reported holding it in 13F filings for Q2 2026, worth $518.9M in total; no superinvestor holds it.
Q2 2024 vs. Q1 2024
How the institutions holding Candel Therapeutics, Inc. changed between Q1 2024 and Q2 2024.
All holders in Q2 2024All holders in Q1 2024
| Measure | Q1 2024 | Q2 2024 | Change |
|---|---|---|---|
| Holders | 20 | 45 | +25 |
| Shares | 3.78M | 5.96M | +2.18M (+57.7%) |
| Value | $5.97M | $37.0M | +$31.0M (+518.9%) |
New holders (31)
Institutions that held Candel Therapeutics, Inc. at the end of Q2 2024 but not at the end of Q1 2024.
Sold out (6)
Institutions that held Candel Therapeutics, Inc. at the end of Q1 2024 and filed for Q2 2024 without it.
| Institution | Shares, Q1 2024 | Value, Q1 2024 |
|---|---|---|
| Mariner, LLC | 33,480 | $52.9K |
| Resources Investment Advisors, LLC. | 29,783 | $47.1K |
| Traphagen Investment Advisors LLC | 17,215 | $27.2K |
| Commonwealth Equity Services, LLC | 14,182 | $22.0K |
| Two Sigma Investments, LP | 13,409 | $21.2K |
| Qube Research & Technologies Ltd | 1 | $2 |